Fascinating interview with a science writer that w

Quote:

---

Fascinating interview with a science writer that worked in the oncology industry.

---

You might want to take what he has to say with a grain of salt. The drug avastin that he goes on an on about as useless is probably better known here as bevacizumab. Bevacizumab and TS-102 are the two drugs that will be used alongside leronlimab in our mssCRC trial. In the trial that led to approval for the bevacizumab/TS-102 combo in CRC, bevacizumab added substantially to overall survival time vs. TS-102 alone. That being said in our trial bevacizumab will add little to no benefit to our trial since bevacizumab and leronlimab are both anti-VEGF. Leronlimab of course is better because our drug does so much more than that.